IGF2BP3 and breast carcinoma: METTL3 also promotes PD-L1 mRNA stability via insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3), thereby impairing T cell-mediated cytotoxicity and reducing anti–PD-L1 therapy efficacy in breast cancer [180].